WALTHAM, Mass.--(BUSINESS WIRE)--
Repligen Corporation (NASDAQ:RGEN) today announced that the Company’s
stock has been added to the Russell 2000® index, a subset of
the Russell 3000® and the Russell Global® indexes.
Russell Investments’ annual
index reconstitution was finalized on June 22, 2012. The Russell
indexes are widely used by investment managers
and institutional investors as proxies for asset allocation and as
performance benchmarks for investment strategies.
“We are pleased that Repligen has been added to the Russell 2000 index,
and believe that our inclusion will enhance our visibility among
institutions that rely on equity indexes as part of their investment
strategy,” stated Walter C. Herlihy, Ph.D., President and Chief
Executive Officer of Repligen.
The Russell 2000 Index measures the performance of the small-cap segment
of the U.S. equity universe. The Russell 2000 is a subset of the Russell
3000 Index and is constructed to provide a comprehensive and unbiased
small-cap barometer. It is reconstituted annually to ensure larger
stocks do not distort the performance and characteristics of the true
small-cap opportunity set. Membership in the Russell 2000 also means
automatic inclusion in the appropriate growth and value style indexes.
Members of the Russell 2000 and 3000 are also included in the Russell
Global Index, which measures the performance of the global equity market
based on all investable equity securities.
About Repligen Corporation
Repligen Corporation is a leading supplier of critical biologic products
used to manufacture biologic drugs. Repligen also applies its expertise
in biologic product development to RG1068, a synthetic hormone being
developed as a novel imaging agent for the diagnosis of a variety of
pancreatic diseases. In addition, the Company has two central nervous
system (CNS) rare disease programs in Phase 1 clinical trials.
Repligen’s corporate headquarters are located at 41 Seyon Street,
Building #1, Suite 100, Waltham, MA 02453. Additional information may be
requested at www.repligen.com.
This press release may contain forward-looking statements within the
meaning of the federal securities laws. Investors are cautioned that
statements in this press release which are not strictly historical
statements including, without limitation, statements identified by words
like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could”
and similar expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from
those anticipated, including, risks discussed from time to time in our
filings with the Securities and Exchange Commission. We expressly
disclaim any responsibility to update forward-looking statements, except
as required by law.
Repligen Corporation
Sondra S. Newman, 781-419-1881
Director
Investor Relations
snewman@repligen.com
Source: Repligen Corporation